Lifeward (LFWD) Registration Filing summary

Company overview and business model

• Designs, develops, and commercializes medical devices for physical rehabilitation and recovery, serving clinical, home, and community settings.

• Core products include ReWalk exoskeletons for spinal cord injury, with FDA-cleared stair and curb functionality in the U.S. and next-generation models pending review.

• Expanded offerings through internal development, distribution agreements, and acquisitions, notably acquiring AlterG for anti-gravity rehabilitation systems in 2023.

• Principal markets are the U.S. and Europe, with direct and distributor-based sales channels; recent agreement with CorLife targets workers' compensation market.

• Research on new products like ReBoot exo-suit is ongoing but currently paused pending further evaluation.

Financial performance and metrics

• Incorporates by reference the Annual Report on Form 10-K for the year ended December 31, 2024, and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

• Financial statements audited by Kost Forer Gabbay & Kasierer, a member of EY Global.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes unless otherwise specified in a prospectus supplement.